Phase I Study of Pembrolizumab Combined With Chemotherapy and Image-Guided Surgery for Treating Malignant Pleural Mesothelioma

What this Trial Is About

Researchers are evaluating the safety, feasibility, and preliminary effects of adding pembrolizumab and image-guided surgery to chemotherapy and surgical treatment for malignant pleural mesothelioma MPM. This phase I trial aims to explore these combined approaches to improve treatment for patients with this disease. Participants will receive pembrolizumab 200 mg through intravenous infusion every three weeks for two cycles before surgery, followed by four cycles after surgery, and continued every three weeks during maintenance. Surgery will include standard procedures with image-guided resection using Indocyanine Green ICG. Post-surgery, participants will also receive chemotherapy with cisplatin and pemetrexed every three weeks for four cycles. Throughout the study, participants will be monitored for adverse events from the start of treatment until 30 days after treatment ends, with serious adverse events tracked up to 90 days post-treatment. Researchers will assess progression-free survival and overall survival from the first treatment until disease progression, death, or study completion. The study duration and follow-up are estimated to last up to two years, with ongoing evaluations to understand treatment effects and safety.

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)